Acacia Research Corporation — Q3 2015 Form 10-Q
Reporting period: Three and nine months ended September 30, 2015; comparisons are to the same 2014 periods. Acacia’s subsidiaries acquire, license and enforce patent rights, with revenue dependent on licensing agreements and litigation outcomes.
Financial results
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $13.0m | $37.2m | $87.5m | $99.8m |
| Operating loss | $26.8m | $12.6m | $39.4m | $46.9m |
| Net loss attributable to Acacia | $27.3m | $12.4m | $44.1m | $49.8m |
| Basic and diluted loss per share | $0.55 | $0.26 | $0.90 | $1.04 |
Operating margins were approximately negative 206% for Q3 and negative 45% for the nine-month period, based on reported operating loss and revenue. Q3 revenue fell 65%, primarily because fewer licensing agreements were executed; year-to-date revenue fell 12%, reflecting fewer agreements and lower average revenue per agreement. Acacia executed 8 agreements in Q3 versus 20 a year earlier, and 51 year to date versus 55.
For the nine months, operating cash flow was $2.2m, versus $13.9m in 2014. Cash and cash equivalents were $157.8m at quarter-end; an additional $10.7m was restricted for a litigation-related guarantee. Cash, cash equivalents and investments, including restricted cash, totaled $168.5m. Working capital, including restricted cash, was $160.6m. The company reported no long-term debt. Current liabilities were $26.7m and total liabilities $28.2m.
Patent amortization was $40.0m year to date; patent assets were $249.5m, goodwill $30.1m, and total equity $439.5m at September 30. Dividends paid in the first nine months were $19.1m ($0.375 per share). The board approved a further $0.125-per-share dividend for payment in November, while future dividends remain discretionary.
Changes and management commentary
- Q3 operating costs and expenses declined 20% year over year, but the revenue decline drove a larger operating loss. Nine-month operating costs declined 13%, contributing to a narrower year-to-date net loss.
- Year-to-date general and administrative expense decreased 19%, partly due to lower stock compensation and personnel costs, including headcount reductions. Q3 litigation and licensing expense rose 8% to $10.3m amid trial preparation and ongoing programs.
- Q3 other operating expense was $3.5m, including accruals for court-ordered attorney fees and settlement and contingency matters.
- Management reported more than 10 patent infringement cases with trial dates scheduled within six months, but emphasized that trial dates may shift and outcomes are difficult to predict. It expects patent-related legal expenses to fluctuate and remain elevated around trials and enforcement activity.
- Management said existing liquidity and anticipated operating cash flows should cover requirements through at least November 2016. It provided no specific revenue or earnings guidance and cautioned that results are uneven and not necessarily indicative of full-year performance.
Risks, contingencies and unusual items
- Revenue is concentrated: three licensees generated 82% of Q3 revenue; two accounted for 57% of nine-month revenue. Three licensees represented 86% of quarter-end receivables.
- A $10.7m cash deposit secures a German-court injunction guarantee. The guarantee may be drawn upon if the ruling is successfully appealed or amended; it renews automatically unless extinguished under applicable procedures.
- Goodwill was not impaired at September 30. The reported fair value exceeded carrying value by 5% using market capitalization alone, or 14% including an estimated control premium. The filing notes that the share price fell to $6.91 by November 3; applying the September carrying value, market capitalization indicated a 20% shortfall, or an 11% shortfall with the control premium. Management viewed the decline as temporary, but adverse trial outcomes or sustained share-price weakness could result in future impairment charges.
- Patent enforcement exposes Acacia to adverse rulings, appeals, sanctions, fee awards, legislative and regulatory changes, and trial delays. Unrecognized tax benefits totaled approximately $2.1m; the company did not expect a significant change in the next 12 months.
- Acacia reported no material change in internal control over financial reporting and concluded disclosure controls were effective.
Important facts for investors to verify
- Whether upcoming trials proceed as scheduled and produce licensing recoveries, and how outcomes affect legal spending and revenue timing.
- Whether revenue concentration and the lower number of agreements persist, and the collection timing of the $12.8m in receivables.
- Whether the share-price decline is sustained and triggers goodwill or patent impairment testing and charges.
- Whether cash generation can support ongoing patent investments, litigation costs and dividends; dividends are board-discretionary.
- The status and potential exposure of the German injunction guarantee and the court-fee, settlement and contingency matters underlying Q3 other expense.